Form 4: ClearPoint Neuro Director Settles Restricted Stock Units

B. Kristine Johnson, a director at ClearPoint Neuro, Inc., settled 21,093 restricted stock units for common stock on May 16, 2025.

Summary

• On May 19, 2025, a Form 4 filing was submitted to the SEC regarding B. Kristine Johnson, a director of ClearPoint Neuro, Inc.
• The filing reports a transaction that occurred on May 16, 2025, where Ms. Johnson settled 21,093 restricted stock units (RSUs) into shares of ClearPoint Neuro common stock.
• Following the transaction, Ms. Johnson directly owns 58,699 shares of ClearPoint Neuro common stock.
• The RSUs were granted on May 16, 2024, and vested on the earlier of the first anniversary of the grant date or the day immediately preceding the company's 2025 annual meeting of stockholders.
• Ms. Johnson has granted power of attorney to Joseph M. Burnett, Ellisa Cholapranee, Danilo D'Alessandro, Jeremy Stigall, and Mazin Sabra to handle SEC filings related to her transactions in ClearPoint Neuro securities.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing related to insider transactions. It doesn't inherently convey positive or negative sentiment, but the conversion of RSUs to stock could be interpreted as a neutral to slightly positive signal.

Positives

• The settlement of RSUs indicates that Ms. Johnson is converting her equity compensation into common stock, which could be seen as a positive sign of her confidence in the company's future.

Industry Context

This is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency into the holdings and transactions of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders, ensuring transparency in accordance with SEC regulations.
• The reporting requirements are consistent across all companies listed on US stock exchanges.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it increases the number of outstanding shares, but the amount is relatively small.

Key Dates

Keywords

Form 4, ClearPoint Neuro, CLPT, restricted stock units, RSU, director, B. Kristine Johnson, beneficial ownership, SEC filing, power of attorney